Botulinum toxin in the treatment of dystonic tics
Identifieur interne : 005C07 ( Main/Exploration ); précédent : 005C06; suivant : 005C08Botulinum toxin in the treatment of dystonic tics
Auteurs : Jankovic [États-Unis]Source :
- Movement Disorders [ 0885-3185 ] ; 1994.
English descriptors
- KwdEn :
- Adolescent, Adult, Blepharospasm (drug therapy), Blinking (drug effects), Botulinum Toxins (administration & dosage), Botulinum Toxins (adverse effects), Botulinum toxin, Dose-Response Relationship, Drug, Dystonia, Dystonia (drug therapy), Follow-Up Studies, Humans, Injections, Intramuscular, Male, Middle Aged, Tic Disorders (drug therapy), Tics, Tourette Syndrome (drug therapy), Tourette's syndrome.
- MESH :
- chemical , administration & dosage : Botulinum Toxins.
- chemical , adverse effects : Botulinum Toxins.
- drug effects : Blinking.
- drug therapy : Blepharospasm, Dystonia, Tic Disorders, Tourette Syndrome.
- Adolescent, Adult, Dose-Response Relationship, Drug, Follow-Up Studies, Humans, Injections, Intramuscular, Male, Middle Aged.
Abstract
Botulinum toxin (BTX) injections provide effective treatment for a variety of disorders manifested by inappropriate muscle contractions, but its efficacy in the treatment of tics has not been previously studied. Ten male patients 13–53 years of age who were diagnosed with Tourette's syndrome manifested by disabling focal tics were included in this pilot study. Five patients had frequent blinking and blepharospasm, rendering them “blind,” and five patients had severe and painful dystonic tics involving their neck muscles. All 10 patients experienced moderate to marked improvement in the intensity and frequency of tics after BTX injections into the involved muscles. Patients in whom premonitory urges preceded their tics noted marked lessening of these sensory symptoms. The benefit lasted 2–20 weeks after injections. There were no serious complications, except for transient ptosis in two and neck pain, stiffness, or weakness in three patients. BTX injections appear to be safe and effective treatment for patients with focal dystonic tics. The treatment ameliorates not only involuntary movements but also the premonitory sensory component associated with some tics.
Url:
DOI: 10.1002/mds.870090315
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 003361
- to stream Istex, to step Curation: 003361
- to stream Istex, to step Checkpoint: 003F43
- to stream PubMed, to step Corpus: 004B03
- to stream PubMed, to step Curation: 004B03
- to stream PubMed, to step Checkpoint: 004B49
- to stream Ncbi, to step Merge: 004855
- to stream Ncbi, to step Curation: 004855
- to stream Ncbi, to step Checkpoint: 004855
- to stream Main, to step Merge: 008D99
- to stream Main, to step Curation: 005C07
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Botulinum toxin in the treatment of dystonic tics</title><author><name sortKey="Jankovic" sort="Jankovic" uniqKey="Jankovic" last="Jankovic">Jankovic</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:FE33AA69F0578AD36537024752EACB3343903481</idno><date when="1994" year="1994">1994</date><idno type="doi">10.1002/mds.870090315</idno><idno type="url">https://api.istex.fr/document/FE33AA69F0578AD36537024752EACB3343903481/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">003361</idno><idno type="wicri:Area/Istex/Curation">003361</idno><idno type="wicri:Area/Istex/Checkpoint">003F43</idno><idno type="wicri:doubleKey">0885-3185:1994:Jankovic:botulinum:toxin:in</idno><idno type="wicri:source">PubMed</idno><idno type="RBID">pubmed:8041378</idno><idno type="wicri:Area/PubMed/Corpus">004B03</idno><idno type="wicri:Area/PubMed/Curation">004B03</idno><idno type="wicri:Area/PubMed/Checkpoint">004B49</idno><idno type="wicri:Area/Ncbi/Merge">004855</idno><idno type="wicri:Area/Ncbi/Curation">004855</idno><idno type="wicri:Area/Ncbi/Checkpoint">004855</idno><idno type="wicri:doubleKey">0885-3185:1994:Jankovic J:botulinum:toxin:in</idno><idno type="wicri:Area/Main/Merge">008D99</idno><idno type="wicri:Area/Main/Curation">005C07</idno><idno type="wicri:Area/Main/Exploration">005C07</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Botulinum toxin in the treatment of dystonic tics</title><author><name sortKey="Jankovic" sort="Jankovic" uniqKey="Jankovic" last="Jankovic">Jankovic</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Parkinson's Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, Houston, Texas</wicri:regionArea><placeName><region type="state">Texas</region></placeName></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="1994">1994</date><biblScope unit="vol">9</biblScope><biblScope unit="issue">3</biblScope><biblScope unit="page" from="347">347</biblScope><biblScope unit="page" to="349">349</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">FE33AA69F0578AD36537024752EACB3343903481</idno><idno type="DOI">10.1002/mds.870090315</idno><idno type="ArticleID">MDS870090315</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adolescent</term><term>Adult</term><term>Blepharospasm (drug therapy)</term><term>Blinking (drug effects)</term><term>Botulinum Toxins (administration & dosage)</term><term>Botulinum Toxins (adverse effects)</term><term>Botulinum toxin</term><term>Dose-Response Relationship, Drug</term><term>Dystonia</term><term>Dystonia (drug therapy)</term><term>Follow-Up Studies</term><term>Humans</term><term>Injections, Intramuscular</term><term>Male</term><term>Middle Aged</term><term>Tic Disorders (drug therapy)</term><term>Tics</term><term>Tourette Syndrome (drug therapy)</term><term>Tourette's syndrome</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Botulinum Toxins</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Botulinum Toxins</term></keywords><keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Blinking</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Blepharospasm</term><term>Dystonia</term><term>Tic Disorders</term><term>Tourette Syndrome</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adolescent</term><term>Adult</term><term>Dose-Response Relationship, Drug</term><term>Follow-Up Studies</term><term>Humans</term><term>Injections, Intramuscular</term><term>Male</term><term>Middle Aged</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Botulinum toxin (BTX) injections provide effective treatment for a variety of disorders manifested by inappropriate muscle contractions, but its efficacy in the treatment of tics has not been previously studied. Ten male patients 13–53 years of age who were diagnosed with Tourette's syndrome manifested by disabling focal tics were included in this pilot study. Five patients had frequent blinking and blepharospasm, rendering them “blind,” and five patients had severe and painful dystonic tics involving their neck muscles. All 10 patients experienced moderate to marked improvement in the intensity and frequency of tics after BTX injections into the involved muscles. Patients in whom premonitory urges preceded their tics noted marked lessening of these sensory symptoms. The benefit lasted 2–20 weeks after injections. There were no serious complications, except for transient ptosis in two and neck pain, stiffness, or weakness in three patients. BTX injections appear to be safe and effective treatment for patients with focal dystonic tics. The treatment ameliorates not only involuntary movements but also the premonitory sensory component associated with some tics.</div></front></TEI><affiliations><list><country><li>États-Unis</li></country><region><li>Texas</li></region></list><tree><country name="États-Unis"><region name="Texas"><name sortKey="Jankovic" sort="Jankovic" uniqKey="Jankovic" last="Jankovic">Jankovic</name></region></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 005C07 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 005C07 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:FE33AA69F0578AD36537024752EACB3343903481
|texte= Botulinum toxin in the treatment of dystonic tics
}}
| This area was generated with Dilib version V0.6.23. |  |